<unk>  refers to a<unk>  consisting of fludarabine, amsacrine, and cytarabine (Ara-C) used as a sequential conditioning therapy for previously untreated patients with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia secondary to MDS (sAML).
FLAMSA regimen
FMR regimen
FMC-R regimen
IFL regimen
RCD regimen
DICE regimen
COPP regimen
FLAMSA-BU regimen